Prognostic value of regional lymph node status in locally advanced gastric cancer after neoadjuvant treatment

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background: Gastric cancer (GC) remains one of the most commonly diagnosed malignancies. Nearly 70% of patients with gastric cancer are diagnosed at a locally advanced stage with a poor prognosis [1]. In recent years, a series of randomized clinical trials, such as MAGIC, FLOT, PRODIGY, and RESOLVE, have consistently confirmed the efficacy of neoadjuvant chemotherapy (NACT) in the treatment of locally advanced gastric cancer. Thus, NACT is the preferred option for patients with locally advanced disease [2–6]. Currently, the ypTNM staging system (AJCC) is the most widely used tool for assessing the prognosis of patients with gastric cancer after NACT [7]. The ypN stage depends on the number of metastatic lymph nodes, and the accuracy of its determination can be affected by dissection of an insufficient number of lymph nodes [8]. Furthermore, several studies have shown that an increased number of lymph nodes removed correlates with a better prognosis. Lymph node ratio (LNR, the proportion of metastatic lymph nodes to all lymph nodes removed) has also been shown to be a more accurate predictor of prognosis in patients with gastric cancer who have undergone radical gastrectomy [9–13]. However, there is limited data on the prognostic value of the LNR in patients with locally advanced gastric cancer after NACT.

Objective: Evaluation of the prognostic value of the LNR in patients with locally advanced gastric cancer after NACT

Materials and methods: Our retrospective study collected data from 210 patients with locally advanced gastric cancer who underwent radical surgery after NACT at the City Clinical Oncology Dispensary from 2020 to the present. Indications for perioperative therapy for gastric cancer include clinical stages cT3-4aN any M0 or cT3-4aN+M0, assessed using CT and endoscopic ultrasonography [14]. All patients underwent regional lymph node assessment based on morphological examination data: the number of examined lymph nodes and the number of affected lymph nodes were assessed, and the ratio of affected to examined lymph nodes was calculated, multiplied by 100 (the LNR index). The optimal cutoff value for the LNR index, which significantly impacts PFS, was determined; this value was > 7.14.

Conclusion: Our study showed that a high LNR index (> 7.14) was significantly associated with worse relapse-free and overall survival in patients who underwent perioperative chemotherapy and radical gastrectomy. The metastatic regional lymph node ratio (LNR) can be used as an independent prognostic factor in patients with resectable gastric cancer.

Full Text

Restricted Access

About the authors

Natalia P. Beliak

Saint Petersburg State University; City Clinical Oncology Dispensary

Email: dr.s.kutukova@gmail.com
ORCID iD: 0000-0003-0402-6067
SPIN-code: 2937-4858

Cand. Sci. (Med.), Associate Professor at the Department of Oncology at the Medical Institute; Head of Department № 10 (Chemotherapy)

Russian Federation, Saint Petersburg; Saint Petersburg

Svetlana I. Kutukova

Saint Petersburg State University; Pavlov First Saint Petersburg State Medical University (Pavlov University)

Author for correspondence.
Email: dr.s.kutukova@gmail.com
ORCID iD: 0000-0003-2221-4088
SPIN-code: 6735-6556

Dr. Sci. (Med.), Professor at the Department of Dentistry, Surgical and Maxillofacial Surgery; Oncologist, Department № 10 (Chemotherapy)

Russian Federation, Saint Petersburg; Saint Petersburg

Natalia V. Smirnova

Saint Petersburg State University

Email: dr.s.kutukova@gmail.com
ORCID iD: 0009-0006-3593-3646

Oncologist, Department № 10 (Chemotherapy)

Russian Federation, Saint Petersburg

Alexandra V. Androsova

Saint Petersburg State University; City Clinical Oncology Dispensary

Email: dr.s.kutukova@gmail.com
ORCID iD: 0000-0001-7111-1507
SPIN-code: 8552-6219

Cand. Sci. (Med.), Assistant at the Department of Oncology at the Medical Institute; Oncologist at the Department № 10 (Chemotherapy)

Russian Federation, Saint Petersburg; Saint Petersburg

Ekaterina A. Mgar

Saint Petersburg State University

Email: dr.s.kutukova@gmail.com
ORCID iD: 0009-0003-6646-9442

Oncologist, Department № 10 (Chemotherapy)

Russian Federation, Saint Petersburg

Anna A. Varankina

Saint Petersburg State University

Email: dr.s.kutukova@gmail.com
ORCID iD: 0009-0007-2182-5684

Oncologist, Department № 10 (Chemotherapy)

Russian Federation, Saint Petersburg

Leylya A. Ksanaeva

Saint Petersburg State University

Email: dr.s.kutukova@gmail.com
ORCID iD: 0009-0003-6381-3076

Oncologist, Department № 10 (Chemotherapy)

Russian Federation, Saint Petersburg

Yury V. Pelipas

Saint Petersburg State University

Email: dr.s.kutukova@gmail.com
ORCID iD: 0000-0003-3647-0445
SPIN-code: 3549-5476

Cand. Sci. (Med.), Head of Department № 4

Russian Federation, Saint Petersburg

Rashida V. Orlova

Saint Petersburg State University; City Clinical Oncology Dispensary

Email: dr.s.kutukova@gmail.com
ORCID iD: 0000-0003-4447-9458
SPIN-code: 9932-6170

Dr. Sci. (Med.), Head of the Department of Oncology at the Medical Institute; Chief Specialist in Drug Treatment and Rehabilitation

Russian Federation, Saint Petersburg; Saint Petersburg

References

  1. Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin.2021;71(3):209–249. https://dx.doi.org/10.3322/caac.21660
  2. Wang Y., Li Z., Shan F., et al. Current status of diagnosis and treatment of early gastric cancer in China--data from China Gastrointestinal Cancer Surgery Union. Zhonghua Wei Chang Wai Ke Za Zhi. 2018;21(2):168–174.
  3. Al-Batran S.E., Homann N., Pauligk C., et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–1957. https://dx.doi.org/10.1016/S0140-6736(18)32557-1
  4. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. https://dx.doi.org/10.1056/NEJMoa055531
  5. Ji J., Shen L., Li Z., et al. Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: a randomized phase III trial (RESOLVE trial). Ann Oncol. 2019;30:877. https://dx.doi.org/10.1093/annonc/mdz394.033
  6. Kang Y.K., Yook J.H., Park Y.K., et al. Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY). Ann Oncol. 2019;30:876877. https://dx.doi.org/10.1200/JCO.20.02914
  7. Kakar S., Pawlik T., Allen P., editors. AJCC cancer staging manual. 8. New York: Springer-Verlag; 2017.
  8. Allen C.J., Vreeland T.J, Newhook T.E., et al. Prognostic value of lymph node yield after neoadjuvant chemoradiation for gastric cancer. Ann Surg Oncol. 2020;27(2):534–542. https://dx.doi.org/10.1245/s10434-019-07840-8
  9. Yamashita K., Hosoda K., Ema A., Watanabe M. Lymph node ratio as a novel and simple prognostic factor in advanced gastric cancer. Eur J Surg Oncol. 2016;42(9):1253–1260. https://dx.doi.org/10.1016/j.ejso.2016.03.001
  10. Bouliaris K., Rachiotis G., Diamantis A., et al. Lymph node ratio as a prognostic factor in gastric cancer patients following D1 resection. Comparison with the current TNM staging system. Eur J Surg Oncol. 2017;43(7):1350–1356. https://dx.doi.org/10.1016/j.ejso.2017.03.013
  11. Son S.Y., Kong S.H., Ahn H.S., et al. The value of N staging with the positive lymph node ratio, and splenectomy, for remnant gastric cancer: a multicenter retrospective study. J Surg Oncol. 2017;116(7):884–893. https://dx.doi.org/10.1002/jso.24737
  12. Chen J.X., Sun J.W., Wang Y., et al. Lymph node ratio-based the ypTNrM staging system for gastric cancer after neoadjuvant therapy: a large population-based study. Surg Today. 2022;52(5):783794.
  13. Zhu K., Jin H., Li Z., et al. The prognostic value of lymph node ratio after neoadjuvant chemotherapy in patients with locally advanced gastric adenocarcinoma. J Gastric Cancer. 2021;21(1):49–62. https://dx.doi.org/10.5230/jgc.2021.21.e5
  14. Jaffer A.A., Thomas A.D., David J.B. (eds).Gastric Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Springer International Publishing. American Joint Commission on Cancer; 2020.
  15. Dindo D., Demartines N., Clavien P.-A.. Classification of surgical complications. Ann Surg. 2004;240:205–213. https://dx.doi.org/10.1097/01.sla.0000133083.54934.ae
  16. Zhang X., Liang H., Li Z., et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081–1092. https://dx.doi.org/10.1016/S1470-2045(21)00297-7
  17. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.
  18. Ajani J.A., D’Amico T.A., Bentrem D.J., et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167–192.
  19. Jomrich G., Paireder M., Kristo I., et al. High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma. Ann Surg. 2021;273(3):532–541. https://dx.doi.org/10.1097/SLA.0000000000003370
  20. Li Z., Li S., Ying X., et al. The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy. Gastric Cancer. 2020;23(3):540–549. https://dx.doi.org/10.1007/s10120-019-01027-6
  21. Gong W., Zhao L., Dong Z., et al. After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients. J Clin Lab Anal. 2018;32(5):e22364. https://dx.doi.org/10.1002/jcla.22364
  22. Grenader T., Waddell T., Peckitt C., et al. Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. Ann Oncol. 2016;27(4):687–692. https://dx.doi.org/10.1093/annonc/mdw012
  23. Migita K., Matsumoto S., Wakatsuki K., et al. A decrease in the prognostic nutritional index is associated with a worse long-term outcome in gastric cancer patients undergoing neoadjuvant chemotherapy. Surg Today.2 017;47(8):1018–1026. https://dx.doi.org/10.1007/s00595-017-1469-y
  24. Sun J., Wang D., Mei Y., et al. Value of the prognostic nutritional index in advanced gastric cancer treated with preoperative chemotherapy. J Surg Res. 2017;209:37–44. https://dx.doi.org/10.1016/j.jss.2016.09.050
  25. Blumenthaler A.N., Newhook T.E., Ikoma N., et al. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol. 2021;123(4):911–922. https://dx.doi.org/10.1002/jso.26367.
  26. Becker K., Mueller J.D., Schulmacher C., et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521–1530. https://dx.doi.org/10.1002/cncr.11660
  27. Tomasello G., Petrelli F., Ghidini M., et al. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: a meta-analysis of 17 published studies. Eur J Surg Oncol.2 017;43(9):1607–1616. https://dx.doi.org/10.1016/j.ejso.2017.03.001
  28. Tang X., He Q., Qu H., et al. Post-therapy pathologic tumor volume predicts survival in gastric cancer patients who underwent neoadjuvant chemotherapy and gastrectomy. BMC Cancer. 2019;19(1):797. https://dx.doi.org/10.1186/s12885-019-6012-7
  29. Park J., Jeon C.H., Kim S.J., et al. A novel approach for gastric cancer staging in elderly patients based on the lymph node ratio. J Gastric Cancer. 2021;21(1):84–92. https://dx.doi.org/10.5230/jgc.2021.21.e9
  30. Huang Z., Chen Y., Zhang W., et al. Modified gastric cancer AJCC staging with a classification based on the ratio of regional lymph node involvement: a population-based cohort study. Ann Surg Oncol. 2020;27(5):1480–1487. doi: 10.1245/s10434-019-08098-w
  31. Pereira M.A., Ramos M., Dias A.R., et al. Lymph node regression after neoadjuvant chemotherapy: a predictor of survival in gastric cancer. J Surg Oncol. 2020;121(5):795–803.
  32. Smyth E.C., Fassan M., Cunningham D., et al. Effect of pathologic tumor response and nodal status on survival in the Medical Research Council adjuvant gastric infusional chemotherapy trial. J Clin Oncol. 2016;34(23):2721–2727. doi: 10.1200/JCO.2015.65.7692
  33. Stark A.P., Estrella J.S., Chiang Y.J., et al. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol. 2020;122(3):422–432. https://dx.doi.org/10.1002/jso.25984
  34. Fujitani K., Mano M., Hirao M., et al. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer. Ann Surg Oncol. 2012;19(6):1936–1943. https://dx.doi.org/10.1245/s10434-011-2165-6

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure. Overall survival and progression-free survival of patients depending оп the LNR index

Download (101KB)
Indexing metadata

Copyright (c) 2025 Bionika Media